Discover Top Posts Tagged with #double-blind

Popular Recent

In related thoughts to the last post (by one @greatwyrmgold), Double-Blind is one of my favorite novels. The main character fits the “jaded but effective and arguably more moral than the ‘moral center’ characters” archetype to a T, just like Taylor Hebert and Zorian Kazinski.

And I’m just now realizing my perception of them is very biased, because one of my less-favored things in media is idea that you can get away with avoiding the trolly problem, that you can just “choose to be good” and everything works out well enough . Edit (sentence I forgot I would need): so I tend to really like characters who break that rule, and I think of them as the most effective (or even the best period) character for that.

And that other post actually reminded me that, no, it is not strictly necessary to pick the most ethically dubious option to be the most effective.

Now, do any of these characters “always go dubious”? No. But they err on the side of ethically dubious, and the narrative often rewards them for it. In real life, it’s not so simple (and I’m aware that this contrasts the usual use of “it’s not so simple” to mean that ethics must be kept at arm’s length to be the most effective at saving people).

#ethics #double-blind #worm #mother of learning #Edit: sorry for tagging you but I thought you’d be interested #Edit 2: added a sentence to make the paragraph transition less awkward

finance and business people: in actuality, finance and business is ultimately about value, and that in itself is only an agreement between two parties, and refers to nothing material or tangible per se. in short, all of our work is opinion, even if it is well-reasoned opinion.

also finance and business people: (behave like just because they have the most amount of money and command the highest prices, therefore they are objectively better, and consequently those who are paid little or not at all are objectively worse and deserve the suffering they get)

also also finance and business people: I didn't say that people are worse because they are underpaid, and you can't prove that I said it.

#finance #kkkapitalizm #eat the rich #double-blind #lies we tell ourselves

“You have to choose what you want to be,” I said, echoing my father’s words from from long ago. Words I’d routinely chosen to ignore. “And you have to keep making that choice. Over and over. Every decision you make is a hammer striking chisel. It’s not as simple as good or bad. It’s never that easy. All that matters is that, at the end of the day, the existence you carve out for yourself is something you’d be happy with.”

#quotes runnerpost #seriously this book is so good.#It’s been like two years since I’ve read it so this isn’t recency bias talking #double-blind

Welcome to see more details about Mazdutide in Phcoker!!

About GLORY-1 (NCT05607680), this Phase 3 clinical trial is evaluating the efficacy and safety of mazdutide in Chinese adults with overweight or obesity. The trial is multi-center, randomized, double-blind, and placebo-controlled, ensuring the highest standards of research. During the 48-week double-blind treatment period, 610 participants were randomized to receive mazdutide 4 mg, 6 mg, or placebo. We are excited to see the results of this groundbreaking study!

The GLORY-1 study was a resounding success! Both mazdutide 4 mg and 6 mg outperformed the placebo in two key areas: the percentage change in body weight from baseline to week 32 and the proportion of participants with a weight loss of ≥5% at week 32. And the best part? The weight-loss efficacy continued to improve from week 32 to week 48!

Furthermore, the study achieved all key secondary endpoints with flying colors! This includes the proportion of participants who experienced significant weight loss of 10% or 15%, as well as improvements in waist circumference, systolic blood pressure, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), total cholesterol, serum uric acid, and alanine aminotransferase (ALT). It's worth noting that mazdutide outperformed the placebo in all of these weight-loss and cardiometabolic endpoints.

During the double-blind treatment period, the safety profile of mazdutide was similar to that observed in previous clinical studies, and no new safety signals were detected. Additionally, its friendly safety profile and lack of new safety signals make it a promising candidate for future treatments. We are confident in the potential of Mazdutide and its ability to positively impact patients' lives.

Excitingly, Mazdutide has become the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials. As the first registration trial for weight management using mazdutide, the results of GLORY-1 not only confirm the efficacy and safety of mazdutide in a large population but also provide high-quality clinical evidence of long-term pharmacotherapy for weight management, specifically for the Chinese population with overweight or obesity.

#double-blind #Mazdutide #MazdutidePhcoker #MazdutideResearch #Mazdutidepeptide #Mazdutidepowder #Mazdutidesupply #Mazdutidemanufacture #Mazdutidesale #MazdutideWeightloss #MazdutideForobesity #MazdutideVSsemaglutide #MazdutideVStirzepatide #MazdutideVSretatrutide #MazdutideVScagrilintide #polypeptide #weight loss #tirzepatide #semaglutide

#double-blind

Trending Tags

Recently Viewed Tags

#double-blind